| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2024―Sep―09 |
4) COVID-19 and Clinical Research in Japan","4）COVID-19と臨床研究 |
Satoshi Kutsuna |
| 2 |
[GO] |
2024―Sep―09 |
2) Virus Research on COVID-19","2）COVID-19のウイルス研究 |
Kei Sato |
| 3 |
[GO] |
2024―Sep―09 |
3) Ethical, Legal and Social Implications on COVID-19","3）COVID-19をめぐる倫理的諸課題 |
Kaori Muto |
| 4 |
[GO] |
2024―Sep―09 |
1) Epidemiology of COVID-19: What We've Learned and Problems","1）COVID-19の疫学：ここまでにわかったことと問題点 |
Hiroshi Nishiura |
| 5 |
[GO] |
2024―Sep―09 |
1. The Challenge of Antimicrobial Resistance (AMR) as a Silent Pandemic","1）サイレント・パンデミックとしての抗菌薬耐性（AMR）の問題 |
Kazuhiro Tateda |
| 6 |
[GO] |
2024―Jul―09 |
BNT162b2接種後の免疫応答賦活化が一因と考えられた治療抵抗性ワクチン関連肺障害の1例","A Suspected Case of COVID-19 Vaccine Induced Immunosuppressive Therapies-resistant Lung Injury due to Activated Immune Responses after BNT162b2 Vaccination |
Atsushi Fujikawa, Yuichiro Takeshita, Jiro Terada, Yasutaka Hirasawa, Kenji Tsushima |
| 7 |
[GO] |
2024―Jul―09 |
SARS-CoV-2 mRNAワクチン接種後に再燃し，治療に難渋した免疫性血小板減少症の1例","Severe, Refractory Cytopenia Following MRNA-based SARS-CoV-2 Vaccination in Preexisting ITP Patient |
Riku Hasebe, Kana Nagashima, Takahisa Mizukoshi, Kento Ono, Saori Shimoyama, Yuji Kanisawa |
| 8 |
[GO] |
2024―Jun―09 |
具体的な地域医療活動 COVID-19の在宅医療への影響","Impact of COVID-19 on Home Health Care |
Jun Sasaki |
| 9 |
[GO] |
2024―Jun―09 |
V．COVID-19蔓延期における肺癌診療","V. Management of Patients with Lung Cancer in the Era of Covid-19 Pandemic |
Yuichi Takiguchi |
| 10 |
[GO] |
2024―Apr―09 |
A Case of Acquired Thrombotic Thrombocytopenic Purpura after BNT162b2 MRNA COVID-19 Vaccination","BNT162b2 mRNA coronavirus disease 2019：COVID-19ワクチン接種後に発症した後天性血栓性血小板減少性紫斑病（aTTP）の1例 |
Kenji Imamura, Mayuko Tsukida, Takashi Maehara, Hiroyuki Noguchi, Hisashi Takei, Kohtaro Toyama |
| 11 |
[GO] |
2024―Mar―09 |
2．Withコロナ時代の院内感染対策","2. Infection Prevention Strategy in COVID-19 Era |
Miki Nagao |
| 12 |
[GO] |
2024―Mar―09 |
7. COVID-19: Recent Topics of Interest","7．COVID-19最近の話題 |
Satoshi Kutsuna |
| 13 |
[GO] |
2024―Mar―09 |
5. Issues to Be Resolved in Asthma Care; Thoughts on Setting Goals for Practice through COVID Pandemic","5．気管支喘息診療に残された課題―コロナ禍を通して診療の目標設定について思うこと― |
Konno Satoshi |
| 14 |
[GO] |
2024―Feb―19 |
2）COVID-19 のウイルス研究","2) Virus Research on COVID-19 |
Kei Sato |
| 15 |
[GO] |
2024―Feb―19 |
4) COVID-19 and Clinical Research in Japan","4）COVID-19 と臨床研究 |
Satoshi Kutsuna |
| 16 |
[GO] |
2024―Feb―19 |
3) Ethical, Legal and Social Implications on COVID-19","3）COVID-19 をめぐる倫理的諸課題 |
Kaori Muto |
| 17 |
[GO] |
2024―Feb―19 |
1）COVID-19 の疫学：ここまでにわかったことと問題点","1) Epidemiology of COVID-19: What We've Learned and Problems |
Hiroshi Nishiura |
| 18 |
[GO] |
2024―Feb―19 |
1. The Challenge of Antimicrobial Resistance (AMR) as a Silent Pandemic","1．サイレント・パンデミックとしての抗菌薬耐性（AMR）の問題 |
Kazuhiro Tateda |
| 19 |
[GO] |
2024―Feb―09 |
COVID-19関連IgA血管炎が疑われた1剖検例","An Autopsy Case of COVID-19-associated IgA Vasculitis |
Miki Nakamura, Fumie Ota, Hiromi Handa, Shinsuke Motegi, Mayuko Tsukida, Takatomo Yoshida, Yoshito Tsukada |
| 20 |
[GO] |
2023―Dec―09 |
Community-based Intervention for COVID-19 Pandemic in Niigata Prefecture","具体的な地域医療活動 新潟県における地域全体での新型コロナウイルス感染症パンデミックへの対応 |
Yoshihisa Tsukada, Yoshinari Tanabe, Yuko Yamashita |
| 21 |
[GO] |
2023―Nov―09 |
III．最新の治療と開発状況","III. Current Treatments and Developments for COVID-19 |
Kei Kasahara, Natsuko Imakita, Tatsuya Fukumori |
| 22 |
[GO] |
2023―Nov―09 |
V．ウィズコロナ時代における感染症医療人材育成","V. Training Healthcare Providers for Infectious Diseases in the Era of COVID-19 |
Akitsugu Furumoto, Shotaro Ide |
| 23 |
[GO] |
2023―Nov―09 |
I. Changes in Infectious Disease Trends Associated with the COVID-19 Pandemic","I．COVID-19パンデミックに伴う感染症発生動向の変化 |
Yoshiaki Gu |
| 24 |
[GO] |
2023―Nov―09 |
IV．新型コロナワクチンの現状と今後の展望","IV. 2022 COVID-19 Vaccine Updates in Japan |
Makoto Saito, Hiroshi Yotsuyanagi |
| 25 |
[GO] |
2023―Nov―09 |
COVID-19：人類とウイルスの共生への道のり","COVID-19: Are the Humankind and the Virus on the Right Rack of the Road from Epidemic to Pandemic to Endemicity? |
Yosuke Aoki |
| 26 |
[GO] |
2023―Nov―09 |
II. Progress in Understanding Characteristics and Pathophysiology of Long COVID","II．Long COVIDの実態と病態解明の進歩 |
Koichi Hirahata |
| 27 |
[GO] |
2023―Oct―09 |
VI．COVID-19と気管支喘息やアレルギー疾患との関わり","VI. The Relationship between COVID-19 and Allergic Diseases Including Asthma |
Hiroyuki Nagase |
| 28 |
[GO] |
2023―Sep―09 |
15. Advances in Immunotherapy for COVID-19 and Infection Control","15．COVID-19 に対する免疫療法の進歩と感染対策 |
Hiroshige Mikamo |
| 29 |
[GO] |
2023―Sep―09 |
5. Present and Future of COVID-19","5．新型コロナウイルス感染症（COVID-19）の現在と未来 |
Nobuhiko Okabe |
| 30 |
[GO] |
2023―Jul―09 |
State-of-art Information of COVID-19-Pathophysiology, Diagnosis, Treatment, and Prevention-","COVID-19―病態・診断治療・予防の最新情報― |
Mashio Nakamura, Junichi Haruta, Kazuki Furuhashi, Yoshikazu Mutoh, Akinari Moriya, Hideo Yasuda, Kenjiro Kunieda |
| 31 |
[GO] |
2023―Jun―09 |
COVID-19流行下における腎臓病診療","Clinical Nephrology during COVID-19 Pandemic |
Motoki Odawara, Mai Sugahara, Masaomi Nangaku |
| 32 |
[GO] |
2023―May―09 |
Protected Code Stroke: Acute Ischemic Stroke Management during Coronavirus Disease 2019 Pandemic","コロナ禍の脳梗塞急性期治療―Protected Code Stroke― |
Teruyuki Hirano |
| 33 |
[GO] |
2023―Mar―09 |
5. Clinical Practice of Respiratory Infectious Diseases in the "with/after COVID-19 Era" |
Hiroshi Mukae |
| 34 |
[GO] |
2023―Mar―09 |
6. Current COVID-19 Topics: COVID-19: Infection Prevention and Control in Health-care Facilities |
Hiroyuki Kunishima |
| 35 |
[GO] |
2023―Feb―19 |
5. Present and Future of COVID-19 |
Nobuhiko Okabe |
| 36 |
[GO] |
2023―Feb―19 |
15. Advances in Immunotherapy for COVID-19 and Infection Control |
Hiroshige Mikamo |
| 37 |
[GO] |
2022―Dec―09 |
A 90-year-old Woman with COVID-19 Infection While Receiving Low-dose Prednisolone and Cyclosporine for the Treatment of Nephrotic Syndrome |
Yuko Sakurai, Hideaki Oka, Saki Iwamoto, Takaki Iwamoto, Mika Kondo, Taro Kamimura |
| 38 |
[GO] |
2022―Nov―09 |
VII. Strengthening Health-care Systems during a Pandemic of COVID-19 |
Tetsuya Matsumoto |
| 39 |
[GO] |
2022―Nov―09 |
V. Current Treatment Approach for COVID-19 |
Satoshi Kutsuna |
| 40 |
[GO] |
2022―Nov―09 |
COVID-19, are We There Yet? |
Koichi Izumikawa |
| 41 |
[GO] |
2022―Nov―09 |
I. Global Epidemiology and Responses of COVID-19 in the Past and the Challenges for the Future |
Kazutoshi Nakashima |
| 42 |
[GO] |
2022―Nov―09 |
VI. Current Status and Future Prospects of COVID-19 Vaccine |
Keiko Tanaka-Taya |
| 43 |
[GO] |
2022―Nov―09 |
IV. Impact of COVID-19 Variants |
Tomoya Saito |
| 44 |
[GO] |
2022―Nov―09 |
II. COVID-19: How Far Has the Pathogenesis been Elucidated? |
Norio Ohmagari |
| 45 |
[GO] |
2022―Nov―09 |
III. Progress in Diagnostic Testing for SARS-CoV-2 |
Miki Nagao |
| 46 |
[GO] |
2022―Sep―09 |
1. SARS-CoV-2: What We Learned So Far |
Yoshihiro Kawaoka |
| 47 |
[GO] |
2022―Sep―09 |
2) Status of Vaccine Development for COVID-19 |
Tokiko Watanabe |
| 48 |
[GO] |
2022―Sep―09 |
3) Advances in Pharmaceutical Treatment and Future Prospects in COVID-19 |
Akihiko Kawana |
| 49 |
[GO] |
2022―Sep―09 |
2) COVID-19: Clinician's Point of View-analysis of Large-scale Japanese Registry |
Haruhito Sugiyama |
| 50 |
[GO] |
2022―Sep―09 |
1) Some problems surfaced by the outbreak of novel coronavirus |
Shutoku Matsuyama |
| 51 |
[GO] |
2022―Sep―09 |
1) Perceptive of Laboratory Diagnosis of SARS-CoV-2 Using Nucleic Acids |
Hayato Miyachi |
| 52 |
[GO] |
2022―Jun―09 |
How Do the Local Hospital Respond to the Outbreak/Cluster Formation of COVID-19 |
Kohta Oyama, Toshikazu Miyakawa, Sadahiro Tamiya |
| 53 |
[GO] |
2022―Jun―09 |
Key Points of Respiratory Care Required for General Physician; with COVID-19 Infection |
Takeshi Isobe |
| 54 |
[GO] |
2022―Jun―09 |
Management of Common Respiratory Disease during the Coronavirus Disease 2019 Pandemic |
Takeshi Isobe, Haruyuki Ishii, Jun Kojima, Ryo Tachikawa, Mirai Matsumura |
| 55 |
[GO] |
2022―Apr―09 |
COVID-19流行期日常診療における慢性閉塞性肺疾患（COPD）の作業診断と管理手順 |
Yoko Shibata, Shigeo Muro, Akihito Yokoyama, and Shu Hashimoto |
| 56 |
[GO] |
2022―Feb―19 |
1. SARS-CoV-2: What We Learned So Far |
Yoshihiro Kawaoka |
| 57 |
[GO] |
2021―Dec―09 |
III. COVID-19-related Coagulopathy, TTP and Antidote for FXa Inhibitors |
Yoshitaka Miyakawa |
| 58 |
[GO] |
2021―Dec―09 |
VIII. Laboratory Diagnosis of Infectious Diseases Including Test for COVID-19: Current Issues and Challenges |
Katsunori Yanagihara |
| 59 |
[GO] |
2021―Nov―09 |
IX. Rheumatic Disease and COVID-19 |
Yasutaka Kimoto, Takahiko Horiuchi |
| 60 |
[GO] |
2021―Nov―09 |
V. Epidemiological Survey and Japanese Response for COVID-19 |
Yura K Ko, Hitoshi Oshitani |
| 61 |
[GO] |
2021―Nov―09 |
III. COVID-19 Activity in Japan and Globally |
Yuuki Tsuchihashi, Tomimasa Sunagawa, Motoi Suzuki |
| 62 |
[GO] |
2021―Nov―09 |
XVI. COVID-19 and Ethical, Legal and Social Implications: Prejudice, Discrimination and Risk Communication |
Kaori Muto |
| 63 |
[GO] |
2021―Nov―09 |
COVID-19. Editorial: COVID-19, Past and Future |
Akihiko Kawana |
| 64 |
[GO] |
2021―Nov―09 |
XIV. A Guide on Clinical Management of Patients with COVID-19 for Front-line Healthcare Workers |
Yasuyuki Kato |
| 65 |
[GO] |
2021―Nov―09 |
VI. Clinical Features of COVID-19 from the Point of View of Infectious Disease Clinician |
Akifumi Imamura |
| 66 |
[GO] |
2021―Nov―09 |
VII. Clinical Features of COVID-19 from the View Point of Respiratory Physician-point of Crossover between Infectious Diseases and Idiopathic Interstitial Pneumonia- |
Jiro Fujita |
| 67 |
[GO] |
2021―Nov―09 |
II. Summary and Chronology of COVID-19 in Japan |
Nobuhiko Okabe |
| 68 |
[GO] |
2021―Nov―09 |
VIII. Clinical Features of COVID-19 in the Aspects of Thrombus, Gerontology, and Therapeutics for Hypertension |
Takuya Kishi, Koichi Node |
| 69 |
[GO] |
2021―Nov―09 |
Discussion on Lesson Learned from First Wave of COVID-19 Pandemic in Japan - from Physician's Point of View - |
Akihiko Kawana, Koichi Izumikawa, Shigeru Omi, Fukumi Nakamura |
| 70 |
[GO] |
2021―Nov―09 |
X. Critical Care Management of Patients with COVID-19 Pneumonia |
Atsuko Shono, Toru Kotani |
| 71 |
[GO] |
2021―Nov―09 |
I. Animal Models of SARS-CoV-2 Infection and Pathogenesis |
Masaki Imai, Yoshihiro Kawaoka |
| 72 |
[GO] |
2021―Sep―09 |
4) Clinical Characteristics and Infection Control Measures of COVID-19 |
Akihiko Kawana |
| 73 |
[GO] |
2021―Sep―09 |
5) Pharmacotherapy of COVID-19 |
Yohei Doi |
| 74 |
[GO] |
2021―Sep―09 |
1) Epidemiology of COVID-19 in Japan: Current Status and Future Perspectives |
Motoi Suzuki |
| 75 |
[GO] |
2021―Sep―09 |
3) COVID-19 Outbreak in Japan |
Takaji Wakita |
| 76 |
[GO] |
2021―Sep―09 |
9) From the Perspective of Endocrinology to Share with Physicians Amid the Coronavirus Pandemic |
Akiyo Tanabe |
| 77 |
[GO] |
2021―Mar―09 |
Novel Coronavirus Disease (COVID-19) |
Akihiko Kawana, Keiichi Mikasa, Koichi Izumikawa |
| 78 |
[GO] |
2021―Feb―09 |
I. Epidemiology of Heart Failure: Heart Failure Pandemic |
Yasuhiko Sakata, Kotaro Nochioka, Hiroaki Shimokawa |
